Sanofi has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) covering Dupixent (dupilumab) across four indications spanning dermatology and respiratory care, the company announced via BioSpace. The agreement signals movement toward coordinated public reimbursement of the biologic in Canada's provincial drug plans.

A letter of intent at the pCPA level is a procedural milestone, not a final listing. It fixes the negotiated terms between the manufacturer and Canada's collective provincial negotiator, and it clears the path for individual provinces and federal plans to list the drug on their formularies. Sanofi confirmed the LOI covers four indications for Dupixent in dermatology and respiratory care; the announcement did not spell out per-indication pricing or listing timelines.

Who is the pCPA and what does the LOI do?

The pCPA negotiates drug prices on behalf of Canada's provinces, territories and federal drug plans. When it signs an LOI with a manufacturer, participating plans can move to list the product under the negotiated terms. Dupixent, a monoclonal antibody targeting IL-4 and IL-13 signaling, has become one of the most widely used biologics across atopic dermatitis, asthma and related type 2 inflammatory diseases worldwide, which makes pCPA-level terms consequential for Canadian prescribers.

For dermatologists, the practical question is formulary access. Atopic dermatitis patients who qualify for Dupixent under provincial plans have historically faced coverage variation across provinces, and a single negotiated price list covering multiple indications tends to standardize that access. The announcement positions dermatology and respiratory indications under one agreement framework rather than piecemeal provincial listings.

What's in the deal?

The announcement, as reported by BioSpace, establishes:

• A letter of intent between Sanofi and the pCPA
• Coverage terms spanning four indications for Dupixent
• A scope that includes both dermatology and respiratory care

The release did not disclose the negotiated price, the confidential rebate structure or the effective dates for provincial listings. Those details typically remain confidential under pCPA practice, and provinces roll out listings on their own schedules after the LOI.

Why it matters for access

Dupixent's Canadian footprint has grown as its approved uses expanded, and reimbursement has lagged approvals in several markets — a pattern familiar to dermatologists who treat moderate-to-severe atopic dermatitis. A multi-indication LOI consolidates negotiation into one instrument, which usually shortens the gap between approval and public coverage. Patients waiting on public-plan coverage for an approved indication are the immediate beneficiaries once provinces act on the negotiated terms.

Respiratory indications under the same umbrella matter to dermatology practices indirectly. Shared negotiation across specialties gives payers a fuller view of the drug's total budget impact, and that can influence how quickly skin-related indications get listed alongside airway ones.

What comes next

Provinces and federal plans will now decide individually whether and when to list Dupixent under the LOI terms. Clinicians should watch their provincial formulary updates for effective dates and criteria changes. Broader coordinated access for Canadian atopic dermatitis and respiratory patients now hinges on how quickly those plans convert the letter of intent into listings.

This article is based on the BioSpace announcement and does not add details beyond what the source disclosed.